-
ASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pc
19 Feb 2024 01:22 GMT
… nasal spray, SPONTAN
Starpharma suffers FDA setback
Starpharma (ASX:SPL) fell -10% … relating to recent product approvals.
Starpharma had engaged highly experienced regulatory … US market in the future, Starpharma will not prioritise conducting another …
-
Starpharma says Viraleze shows antiviral efficacy in COVID-19 patients
30 Jan 2024 07:46 GMT
Starpharma (ASX:SPL) has … infection control of populations.”
Starpharma’s CEO Cheryl Maley said … These results are consistent with Starpharma’s nonclinical studies, which … viruses, including human coronaviruses.
“Starpharma is grateful to the Principal …
-
ASX Health Stocks: Starpharma says Viraleze reduces viral load in nose, effective in Covid-19
29 Jan 2024 02:05 GMT
Starpharma says Viraleze is effective … ’s Orphan Drug application
Starpharma says Viraleze is effective in … Covid-19
Starpharma (ASX:SPL) announced that … placebo was not statistically significant.
Starpharma says these findings are consistent …
-
Starpharma Holdings Limited (OTCMKTS:SPHRY) Short Interest Up 78.8% in December
01 Jan 2024 03:37 GMT
… presently 1.2 days.
Starpharma Price Performance
SPHRY remained … average is $1.30.
Starpharma Company Profile
(Get Free … More Great Investing Ideas?
Starpharma Holdings Limited, a biopharmaceutical … ' ratings for Starpharma and related companies with …
-
Starpharma’s dendrimer platform meets metastatic cancer endpoints in phase II
23 Dec 2023 00:20 GMT
Starpharma Holdings Ltd.’s DEP docetaxel …
-
ASX Health Stocks: dorsaVi up 27pc on US deals, Starpharma reports positive outcome on Phase 2 trial
19 Dec 2023 02:59 GMT
… on Phase 2 trial
Starpharma Holdings (ASX:SPL) … findings, in addition to Starpharma’s recently reported results … programs, will feed into Starpharma’s ongoing commercial discussions … for the products,” said Starpharma CEO, Dr Jackie Fairley.
…
-
ASX Health Stocks: Noxopharm jumps +50pc on mRNA vaccine results; Starpharma +25pc on Phase 2 study
18 Oct 2023 00:42 GMT
… mRNA testing of SOF-VAC
Starpharma jumped 25pc after completing Phase … 25pc on Phase 2 results
Starpharma (ASX:SPL) surged 25% after … with standard-of-care paclitaxel.
Starpharma says these results create significant …
-
Starpharma Holdings Limited (OTCMKTS:SPHRY) Sees Large Decline in Short Interest
29 Sep 2023 16:21 GMT
… currently 0.5 days.
Starpharma Stock Performance
Starpharma stock opened at $1 … )
Want More Great Investing Ideas?
Starpharma Holdings Limited, a biopharmaceutical company … and analysts' ratings for Starpharma and related companies with MarketBeat …
-
Starpharma announces the presentation of DEP irinotecan combination data
28 Sep 2023 04:43 GMT
… programs, including DEP irinotecan and Starpharma’s radiotheranostic, DEP HER2- … irinotecan combination poster builds on Starpharma’s recently released positive … advanced platinum-resistant ovarian cancer.
Starpharma said the DEP irinotecan combination …
-
ASX Health Stocks: Starpharma full steam ahead on VIRALEZE study, Dimerix to use QYTOVRA as brand name
25 Sep 2023 02:34 GMT
… brand name by US FDA
Starpharma completes recruitment for VIRALEZE study … Nina Webster, CEO of Dimerix.
Starpharma completes VIRALEZE study recruitment in … UK
Starpharma (ASX:SPL) has completed recruitment …